Item 8.01 Other Events
On
Additionally, the Company announced that it expects to receive another 500,000 rapid tests from the manufacturer in the next two to three weeks in order to fulfill additional customer orders.
Forward-Looking Statement
This current report on Form 8-K includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements
other than statements of historical facts contained in this presentation, are
forward-looking statements. Forward-looking statements are generally written in
the future tense and/or are preceded by words such as ''may,'' ''will,''
''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,''
''believe,''''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or
similar words, or the negatives of such terms or other variations on such terms
or comparable terminology. These statements are just predictions and are subject
to risks and uncertainties that could cause the actual events or results to
differ materially. These risks and uncertainties include, among others: market
and other conditions, the regulatory and commercial risks associated with
introducing the COVID-19 IgG/IgM Rapid Test, shipping delays and their impact on
our ability to introduce the COVID-19 IgG/IgM Rapid Test, our ability to enforce
our exclusive rights to distribute the COVID-19 IgG/IgM Rapid Test in the
jurisdictions set forth in the distribution agreement, the ability of the
COVID-19 IgG/IgM Rapid Test to accurately and reliably test for COVID-19, the
manufacture of the COVID-19 IgG/IgM Rapid Test's ability to manufacture such
testing kits on a high volume scale, manufacturing problems or delays related to
the COVID-19 IgG/IgM Rapid Test, our ability to satisfy any labelling conditions
or other FDA or other regulatory conditions to sell the COVID-19 IgG/IgM Rapid
Test Kit, the ability to obtain a sufficient number of COVID-19 IgG/IgM Rapid
Test kits to meet demand if any, the demand or lack thereof for the COVID-19
IgG/IgM Rapid Test Kit, effects of the business combination of Aytu and the
Commercial Portfolio and the recently completed merger ("Merger") with
Item 9.01 Financial Statements and Exhibits.
(d) The following exhibit is being filed herewith:
Exhibit Description 99.1 Press release announcement datedApril 1, 2020 1
© Edgar Online, source